Seres therapeutics announces achievement of target enrollment in ser-287 phase 2b eco-reset study for ulcerative colitis

Cambridge, mass.--(business wire)--seres therapeutics, inc. (nasdaq: mcrb) announced today that the company has achieved target enrollment of the phase 2b eco-reset clinical study of ser-287 in patients with mild-to-moderate ulcerative colitis (uc) in both the u.s. and canada. ser-287, seres' second microbiome therapeutic to reach late-stage clinical trials following a successful phase 3 readout for ser-109, could represent a new therapeutic paradigm for uc by targeting underlying biological dr
MCRB Ratings Summary
MCRB Quant Ranking